On January 31, 2018, the Board of Directors of OncoMed Pharmaceuticals, Inc. appointed John Lewicki, Ph.D., the company's Executive Vice President, Research and Development, and a member of the Office of the President, as the company's President and eliminated the Office of the President. The Compensation Committee of the company's Board of Directors is evaluating Dr. Lewicki's compensation in light of this appointment. On January 28, 2018, Sunil Patel, the company's Executive Vice President and Chief Financial Officer, Principal Accounting Officer, and a member of the Office of the President at the time, notified the company of his intention to resign from the company, effective on or about March 9, 2018.